Microbiological assay for ceftazidime injectionDE HARO MORENO, Andréia; NUNES SALGADO, Hérida Regina.Journal of AOAC International. 2007, Vol 90, Num 5, pp 1379-1382, issn 1060-3271, 4 p.Article

Population pharmacokinetics of ceftazidime in burn patientsDAILLY, Eric; PANNIER, Michel; JOLLIET, Pascale et al.British journal of clinical pharmacology. 2003, Vol 56, Num 6, pp 629-634, issn 0306-5251, 6 p.Article

High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitutionCARTELLE, Monica; DEL MAR TOMAS, Maria; MOLINA, Francisca et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 6, pp 2308-2313, issn 0066-4804, 6 p.Article

Ceftazidim. IIMARGET, W; GABLER-SANDBERGER, E; TOLXDORFF-NEUTZLING, R et al.Infection. 1987, Vol 15, pp 143-219, issn 0300-8126, suppl. 4Serial Issue

A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignanciesDAILLY, Eric; BRUN, Anne; KERGUERIS, Marie-France et al.International journal of antimicrobial agents. 2006, Vol 27, Num 6, pp 553-556, issn 0924-8579, 4 p.Article

Synergistic potential of ceftazidime plus amikacin or levofloxacin against Pseudomonas aeruginosa as determined using a checkerboard and a disk diffusion techniqueMONTANARI, Maria Pia; PICCOLI, Laura; MINGOIA, Marina et al.Diagnostic microbiology and infectious disease. 2005, Vol 53, Num 2, pp 157-160, issn 0732-8893, 4 p.Article

Development of high-level ceftazidime resistance via single-base substitutions of bla_CTX-M-3 in hyper-mutable Escherichia coliKARISIK, E; ELLINGTON, M. J; PIKE, R et al.Clinical microbiology and infection. 2006, Vol 12, Num 8, pp 803-806, issn 1198-743X, 4 p.Article

In vitro selection and characterization of mutants in TEM-1-producing Escherichia coli by ceftazidime and ceftibutenPERILLI, M; SEGATORE, B; TAVIO, M et al.Journal of chemotherapy. 2007, Vol 19, Num 2, pp 123-126, issn 1120-009X, 4 p.Article

Sensitivity and specificity of various β-lactam antibiotics and phenotypical methods for detection of TEM, SHV and CTX-M extended-spectrum β-lactamasesBEDENIC, B; VRANES, J; MIHALJEVIC, Lj et al.Journal of chemotherapy. 2007, Vol 19, Num 2, pp 127-139, issn 1120-009X, 13 p.Article

Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase -producing Escherichia coliCAO BIN; WANG HUI; ZHU RENYUAN et al.Diagnostic microbiology and infectious disease. 2006, Vol 56, Num 4, pp 351-357, issn 0732-8893, 7 p.Article

Simulation des Selektionsdrucks der Antibiotika Ciprofloxacin und Ceftazidim in Oberflächengewässern mittels klassischer Methoden = Simulation of the selection pressure of the antibiotics ciprofloxacin and ceftazidim in surface waters by means of classic methodsWIETHAN, Jürgen; AL-AHMAD, Ali; HENNINGER, Almut et al.Vom Wasser. 2000, Vol 95, pp 107-118, issn 0083-6915Article

Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumanniiHERITIER, C; POIREL, L; NORDMANN, P et al.Clinical microbiology and infection. 2006, Vol 12, Num 2, pp 123-130, issn 1198-743X, 8 p.Article

Ceftazidime determination in serum by high-pressure liquid chromatographyHUMBERT, Till; RÜMELIN, Andreas; FAUTH, Ulrich et al.Arzneimittel-Forschung. 2004, Vol 54, Num 6, pp 320-322, issn 0004-4172, 3 p.Article

ETUDE DE LA STABILITÉ DES SERINGUES DE VANCOMYCINE ET DE CEFTAZIDIME DESTINÉES À LA VOIE INTRA-VITRÉENNE = STUDY OF THE STABILITY OF THE SYRINGES OF VANCOMYCINE AND CEFTAZIDIME INTENDED FOR THE INTRAVITREAL ROUTEYOUSFI, M. A; JNEN, F; DRIDI, M et al.R.T.S.M. Revue tunisienne de la santé militaire. 2012, Vol 14, Num 2, pp 70-75, issn 0330-5597, 6 p.Article

Prevalence of IS_Aba1 in epidemiologically unrelated Acinetobacter baumannii clinical isolatesRUIZ, Marc; MARTI, Sara; FERNANDEZ-CUENCA, Felipe et al.FEMS microbiology letters. 2007, Vol 274, Num 1, pp 63-66, issn 0378-1097, 4 p.Article

Resistance to ceftazidime in Escherichia coli associated with AcrR, MarR and PBP3 mutations and overexpression of sdiATAVIO, María M; AQUILI, Virginia D; VILA, Jordi et al.Journal of medical microbiology. 2014, Vol 63, Num 1, pp 56-65, issn 0022-2615, 10 p.Article

Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitroTUNNEY, Michael M; SCOTT, Eileen M.Journal of microbiological methods. 2004, Vol 57, Num 1, pp 107-114, issn 0167-7012, 8 p.Article

Evaluation de l'élimination de la ceftazidime par hémofiltration in vitro = Evaluation of ceftazidime elimination by in vitro hemofiltrationJACQUES, V; BARRAUD, F; DUPUIS, A et al.Pharmacie hospitalière française. 1997, pp 54-56, issn 0369-9579, NSConference Paper

Mutational Events in Cefotaximase Extended-Spectrum β-Lactamases of the CTX-M-1 Cluster Involved in Ceftazidime ResistanceNOVAIS, Angela; CANTON, Rafael; COQUE, Teresa M et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 7, pp 2377-2382, issn 0066-4804, 6 p.Article

Novel shv-derived extended-spectrum β-lactamase, SHV-57, that confers resistance to ceftazidime but not cefazolinLING MA; ALBA, Jimena; CHANG, Feng-Yee et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 2, pp 600-605, issn 0066-4804, 6 p.Article

Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patientsCHERNOBELSKI, Pnina; LAVRENKOV, Konstantin; RIMAR, Doron et al.Chemotherapy (Basel). 2006, Vol 52, Num 4, pp 185-189, issn 0009-3157, 5 p.Article

Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulationsGEORGES, Bernard; CONIL, Jean-Marie; RUIZ, Stéphanie et al.British journal of clinical pharmacology. 2012, Vol 73, Num 4, pp 588-596, issn 0306-5251, 9 p.Article

Characterization of Extended-Spectrum β-Lactamases in Enterobacteriaceae Causing Nosocomial Infections in a Zagreb University HospitalJAJIC-BENCIC, I; BEDENIC, B; MIKOC, A et al.Journal of chemotherapy (Testo stampato). 2009, Vol 21, Num 3, pp 282-289, issn 1120-009X, 8 p.Article

Development of extended-spectrum activity in TEM β-lactamases in hyper-mutable, muts Escherichia coliELLINGTON, M. J; LIVERMORE, D. M; PITT, T. L et al.Clinical microbiology and infection. 2006, Vol 12, Num 8, pp 800-803, issn 1198-743X, 4 p.Article

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic modelALOU, Luis; AGUILAR, Lorenzo; SEVILLANO, David et al.Journal of antimicrobial chemotherapy (Print). 2005, Vol 55, Num 2, pp 209-213, issn 0305-7453, 5 p.Article